Skip to main content
SpringerLink
Log in

Multiple Sclerosis

Current Concepts in Management

  • Practical Therapeutics
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Multiple sclerosis is a chronic, often progressive disease of the central nervous system which can produce visual, sensory, motor, and genitourinary dysfunction. Although there is no cure, many disabling symptoms can be ameliorated. Baclofen is the treatment of choice for spasticity and is usually given in doses of 30 to 80 mg/day, although higher doses may be used.

Bladder symptoms in multiple sclerosis generally fall into the categories of failure to store, failure to empty, and mixed types. Most patients can be managed after obtaining a urine culture and sensitivity and post- voiding residual. A variety of anticholinergic agents plus intermittent self- catheterisation is usually the most effective treatment for bladder dysfunction. Prevention of infection is accomplished by urinary acidifiers or low- dose antibiotics.

There is no evidence that long term use of corticosteroids has a beneficial effect on the outcome of multiple sclerosis, although they appear to be useful in hastening the recovery time from an acute exacerbation. There are a number of experimental therapeutic agents which are used to modulate the immune response, which may prove to be of use in slowing or arresting the progression of multiple sclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aimard, G.; Confarreux, C; Trovillas, P. et al.: Our experience of azathioprine treatment in multiple sclerosis; in Delmotte et al. (Eds) Immunosuppressive Treatment in Multiple Sclerosis, pp.3–220 (European Press, Ghent 1979).

    Google Scholar 

  • Blaivas, J.G.: Management of bladder dysfunction in multiple sclerosis. Neurology 30: 12–18 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Bolton, C.; Allsopp, G. and Curzner, M.L.: The effect of cyclosporin A on the adaptive transfer of EAE in the rat. Clinical and Experimental Immunology 47: 127–132 (1982).

    PubMed  CAS  Google Scholar 

  • Bornstein, M.B.; Miller, A.; Teitelbaum, D.; Arnon, R. and Sela, M.: Treatment of multiple sclerosis with a synthetic polypeptide. Preliminary results. Annals of Neurology 8: 117 (1980).

    Google Scholar 

  • Bozek, C.B.; Kastrukoff, Z.F.; Wright, J.; Perry, T. and Paty, D.W.: A double-blind crossover trial of INH in the treatment of action tremor associated with multiple sclerosis. Neurology 34 (Suppl. 1): 128 (1984).

    Google Scholar 

  • Dimitrijevic, M.R. and Sherwood, A.M.: Spasticity: Medical and surgical treatment. Neurology 30: 19–27 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Dowling, P.C.; Bosch, V.V. and Cook, S.D.: Possible beneficial effect of high-dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis. Neurology 30: 33–36 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Ellison, G. and Myers, L.W.: Immunosuppressive drugs in multiple sclerosis. Neurology 30: 28–32 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Goldstein, N.P.; McGuckin, W.F.; McKenzie, B.F. and Mattoy, V.R.: Experimental intrathecal administration of methylpred-nisolone acetate in multiple sclerosis. Transactions of the American Neurological Association 95: 243–244 (1970).

    PubMed  CAS  Google Scholar 

  • Gonsette, R.E.; Delmotte, P. and Demonty, L.: Failure of basic protein therapy of multiple sclerosis. Journal of Neurology 216: 27–31 (1977a).

    Article  PubMed  CAS  Google Scholar 

  • Gonsette, R.E.; Demonty, L. and Delmotte, P.: Intensive immunosuppression with cyclophosphamide in multiple sclerosis; in Delmotte et al. (Eds ) Immunosuppressive Treatment in Multiple Sclerosis, pp.116–131 (European Press, Ghent 1977b).

    Google Scholar 

  • Hallett, M.; Lindsey, J.W.; Adelstein, B.D. and Riley, P.O.: Double-blind trial of Isoniazid for severe postural cerebellar tremor. Neurology 34 (Suppl. 1): 128 (1984).

    Google Scholar 

  • Hauser, S.C.; Dawson, D.M.; Lehrich, J.R.; Beal, F.; Kevy, S.V.; Propper, R.D.; Mills, J.A. and Weiner, H.L.: Intensive immunosuppression in progressive multiple sclerosis. New England Journal of Medicine 308: 173–180 (1983).

    Article  PubMed  CAS  Google Scholar 

  • Hommes, O.R. and Lamers, K.J.B.: Immunosuppressive treatment in chronic progressive multiple sclerosis; in Delmotte et al. (Eds) Immunosuppressive Treatment in Multiple Sclerosis, pp.48–64 (European Press, Ghent 1977).

    Google Scholar 

  • Huddlestone, J. and Oldstone, M.B.A.: T suppressor lymphocytes fluctuate in parallel with changes in the clinical course of patients with multiple sclerosis. Journal of Immunology 123: 1615–1618 (1979).

    CAS  Google Scholar 

  • Jacobs, L.; O’Malley, J.; Freeman, A. and Ekes, R.: Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 214: 1026–1028 (1981).

    Article  PubMed  CAS  Google Scholar 

  • Keys, T.F. and Edson, R.S.: Antimicrobial agents in urinary tract infections. Mayo Clinic Proceedings 58: 165–168 (1983).

    PubMed  CAS  Google Scholar 

  • Muller, R.: Studies on disseminated sclerosis with special reference to symptomatology, course and prognosis. Acta Medica Scandinavica 133 (Suppl. 222): 1–124 (1949).

    Google Scholar 

  • Neighbour, A.P. and Bloom, B.R.: Absence of virus-induced lymphocyte suppression and interferon production in multiple sclerosis. Proceedings of the National Academy of Sciences of the USA 76: 476–480 (1979).

    Article  PubMed  CAS  Google Scholar 

  • Parsons, C.L.: The bladder in multiple sclerosis; in Hallpike et al. (Eds). Multiple Sclerosis, pp.579–602 (Williams and Wilkins, Baltimore 1983).

    Google Scholar 

  • Poser, S.: Diseases of the myelin sheath; in Baker and Bolon (Eds) Clinical Neurology, Vol. 2, pp.65–68 (C.V. Mosby, Illinois 1978).

    Google Scholar 

  • Raine, C.S.; Traugott, U. and Stone, S.M.: Suppression of chronic allergic encephalomyelitis: Relevance to multiple sclerosis. Science 201: 445–448 (1978).

    Article  PubMed  CAS  Google Scholar 

  • Reinherz, E.; Weiner, H.L.; Hauser, S.L.; Cohen, J.A.; Distasa, J.A. and Schlossman, S.F.: Loss of suppressor T cells in active multiple sclerosis: Analysis with monoclonal antibodies. New England Journal of Medicine 303: 125–129 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Romine, J.S. and Salk, J.: A study of MBP as a therapeutic probe in patients with multiple sclerosis; in Hallpike et al. (Eds) Multiple Sclerosis, pp.621–631 (Williams and Wilkins, Baltimore 1983).

    Google Scholar 

  • Rose, A.S.; Kuzma, J.W.; Kurtzske, J. et al.: Cooperative study in the evaluation of therapy in MS: ACTH vs. placebo. Neurology 20: 1–59 (1970).

    PubMed  CAS  Google Scholar 

  • Rosen, J.A.: Prolonged azathioprine treatment of non-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 42: 338–344 (1979).

    Article  CAS  Google Scholar 

  • Rosen, J.A.: Further experience with Azathioprine in multiple sclerosis. Proceedings of the Workshop on Immunosuppressive therapy in multiple sclerosis, Nymeegen, the Netherlands (1982).

  • Sabra, A.F.; Hallett, M.; Sudarsky, L. and Mullally, W.: Treatment of action tremor in multiple sclerosis with isoniazid. Neurology 32: 912–913 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Salonen, R.; Honen, J.; Reunanen, M.; Nikoskelainen, J. and Salmi, A.: PPD-, PWM-, and PHA-induced interferon in stable multiple sclerosis. Annals of Neurology 11: 279–284 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Scheinberg, L.C. and Giesser, B.: INH in multiple sclerosis. Neurology 34: 134 (1984).

    Article  Google Scholar 

  • Schumacher, G.; Beebe, G.; Kibler, R.F. et al.: Problems of experimental trials of therpay in multiple sclerosis. Annals of the New York Academy of Sciences 122: 552 (1965).

    Article  Google Scholar 

  • Tourtellotte, W.W. and Baumhefner, R.W.: Comprehensive management of multiple sclerosis; in Hallpike et al. (Eds) Multiple Sclerosis, pp.513–578 (Williams and Wilkins, Baltimore 1983).

    Google Scholar 

  • Tourtellotte, W.W.; Baumhefner, R.; Potvin, A.; Ma, B.I.; Potvin, J.H.; Mendez, M. and Syndulko, K.: Multiple sclerosis de novo IgG synthesis: Effect of ACTH and corticosteroids. Neurology 30: 1155–1162 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Van Buren, C.T.; Kerman, R.; Agostino, G.; Payne, W.; Flechner, S. and Kahan, B.D.: The cellular target of cyclosporin A action in humans. Surgery 92: 167–174 (1982).

    PubMed  Google Scholar 

  • Wilkinson, S.P.; Portmann, B. and Williams, R.: Hepatitis from dantrolene sodium. Gut 20: 33–36 (1979).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Albert Einstein College of Medicine, Yeshiva University, 1200 Morris Park Avenue, Bronx, New York, New York, 10461, USA

    Barbara Giesser

  2. Medical Rehabilitation Research and Training Center for Multiple Sclerosis, New York, USA

    Barbara Giesser

Authors
  1. Barbara Giesser
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giesser, B. Multiple Sclerosis. Drugs 29, 88–95 (1985). https://doi.org/10.2165/00003495-198529010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198529010-00004

Keywords

Search

Navigation